Insider Buying: Standard BioTools (NASDAQ:LAB) Director Purchases 125,000 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 125,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was bought at an average price of $1.42 per share, with a total value of $177,500.00. Following the transaction, the director directly owned 71,875,000 shares in the company, valued at $102,062,500. This trade represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Thursday, December 4th, Casdin Partners Master Fund, L acquired 150,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.45 per share, with a total value of $217,500.00.
• On Wednesday, December 3rd, Casdin Partners Master Fund, L purchased 75,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.44 per share, with a total value of $108,000.00.
• On Tuesday, November 25th, Casdin Partners Master Fund, L purchased 7,550,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.30 per share, for a total transaction of $9,815,000.00.
• On Monday, November 24th, Casdin Partners Master Fund, L bought 150,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.43 per share, for a total transaction of $214,500.00.
• On Thursday, November 20th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.30 per share, with a total value of $585,000.00.
• On Wednesday, November 19th, Casdin Partners Master Fund, L purchased 350,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.28 per share, for a total transaction of $448,000.00.
• On Tuesday, November 18th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.23 per share, for a total transaction of $338,250.00.
• On Monday, November 17th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.22 per share, for a total transaction of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.24 per share, for a total transaction of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.20 per share, with a total value of $540,000.00.

Standard BioTools Stock Performance

LAB remained flat at $1.44 on Thursday. The company had a trading volume of 1,185,059 shares, compared to its average volume of 2,075,536. The company has a market capitalization of $553.78 million, a PE ratio of -4.24 and a beta of 1.24. The stock’s fifty day simple moving average is $1.30 and its two-hundred day simple moving average is $1.26. Standard BioTools Inc. has a 12-month low of $0.92 and a 12-month high of $2.25.

Hedge Funds Weigh In On Standard BioTools

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in Standard BioTools during the 1st quarter worth about $171,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Standard BioTools by 115.6% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after purchasing an additional 14,541 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Standard BioTools by 0.4% in the first quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company’s stock valued at $18,603,000 after purchasing an additional 69,104 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Standard BioTools by 4.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,443,060 shares of the company’s stock worth $2,639,000 after purchasing an additional 110,411 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Standard BioTools during the 1st quarter worth $862,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on LAB. TD Cowen decreased their target price on Standard BioTools from $1.55 to $1.35 and set a “hold” rating for the company in a research note on Wednesday, November 5th. Wall Street Zen lowered Standard BioTools from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th. Cowen downgraded shares of Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.